vs

Side-by-side financial comparison of NewtekOne, Inc. (NEWT) and Oncology Institute, Inc. (TOI). Click either name above to swap in a different company.

Oncology Institute, Inc. is the larger business by last-quarter revenue ($142.0M vs $73.3M, roughly 1.9× NewtekOne, Inc.). NewtekOne, Inc. runs the higher net margin — 111.8% vs -5.3%, a 117.1% gap on every dollar of revenue. On growth, Oncology Institute, Inc. posted the faster year-over-year revenue change (41.6% vs -2.7%). Oncology Institute, Inc. produced more free cash flow last quarter ($2.2M vs $-579.3M). Over the past eight quarters, Oncology Institute, Inc.'s revenue compounded faster (22.5% CAGR vs 12.2%).

NewTek, Inc., is a hardware and software company, based in San Antonio, Texas, that produced live and post-production video tools and visual imaging software for personal computers. The company was founded in 1985 in Topeka, Kansas, United States, by Tim Jenison and Paul Montgomery. On April 1, 2019, it was announced that NewTek would be acquired by Vizrt.

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

NEWT vs TOI — Head-to-Head

Bigger by revenue
TOI
TOI
1.9× larger
TOI
$142.0M
$73.3M
NEWT
Growing faster (revenue YoY)
TOI
TOI
+44.3% gap
TOI
41.6%
-2.7%
NEWT
Higher net margin
NEWT
NEWT
117.1% more per $
NEWT
111.8%
-5.3%
TOI
More free cash flow
TOI
TOI
$581.5M more FCF
TOI
$2.2M
$-579.3M
NEWT
Faster 2-yr revenue CAGR
TOI
TOI
Annualised
TOI
22.5%
12.2%
NEWT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NEWT
NEWT
TOI
TOI
Revenue
$73.3M
$142.0M
Net Profit
$19.5M
$-7.5M
Gross Margin
Operating Margin
-4.9%
Net Margin
111.8%
-5.3%
Revenue YoY
-2.7%
41.6%
Net Profit YoY
6.6%
43.0%
EPS (diluted)
$0.64
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEWT
NEWT
TOI
TOI
Q4 25
$73.3M
$142.0M
Q3 25
$74.9M
$136.6M
Q2 25
$70.2M
$119.8M
Q1 25
$66.3M
$104.4M
Q4 24
$75.4M
$100.3M
Q3 24
$62.8M
$99.9M
Q2 24
$61.1M
$98.6M
Q1 24
$58.3M
$94.7M
Net Profit
NEWT
NEWT
TOI
TOI
Q4 25
$19.5M
$-7.5M
Q3 25
$17.9M
$-16.5M
Q2 25
$13.7M
$-17.0M
Q1 25
$9.4M
$-19.6M
Q4 24
$18.3M
$-13.2M
Q3 24
$11.9M
$-16.1M
Q2 24
$10.9M
$-15.5M
Q1 24
$9.7M
$-19.9M
Operating Margin
NEWT
NEWT
TOI
TOI
Q4 25
-4.9%
Q3 25
-5.9%
Q2 25
-9.4%
Q1 25
-9.5%
Q4 24
-11.9%
Q3 24
-13.9%
Q2 24
-16.6%
Q1 24
-19.0%
Net Margin
NEWT
NEWT
TOI
TOI
Q4 25
111.8%
-5.3%
Q3 25
23.9%
-12.1%
Q2 25
19.5%
-14.2%
Q1 25
14.1%
-18.8%
Q4 24
24.3%
-13.1%
Q3 24
19.0%
-16.1%
Q2 24
17.9%
-15.7%
Q1 24
16.6%
-21.0%
EPS (diluted)
NEWT
NEWT
TOI
TOI
Q4 25
$0.64
$-0.04
Q3 25
$0.67
$-0.14
Q2 25
$0.52
$-0.15
Q1 25
$0.35
$-0.21
Q4 24
$0.70
$-0.14
Q3 24
$0.45
$-0.18
Q2 24
$0.43
$-0.17
Q1 24
$0.38
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEWT
NEWT
TOI
TOI
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$819.9M
Stockholders' EquityBook value
$397.6M
$-15.7M
Total Assets
$2.7B
$164.7M
Debt / EquityLower = less leverage
2.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEWT
NEWT
TOI
TOI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$9.9M
Q1 24
$29.8M
Total Debt
NEWT
NEWT
TOI
TOI
Q4 25
$819.9M
Q3 25
$748.5M
Q2 25
$657.3M
Q1 25
$774.0M
Q4 24
$708.0M
Q3 24
$655.8M
Q2 24
$652.0M
Q1 24
$662.5M
Stockholders' Equity
NEWT
NEWT
TOI
TOI
Q4 25
$397.6M
$-15.7M
Q3 25
$386.7M
$-12.3M
Q2 25
$312.2M
$-9.0M
Q1 25
$302.3M
$5.1M
Q4 24
$296.3M
$3.6M
Q3 24
$281.8M
$15.5M
Q2 24
$274.0M
$29.2M
Q1 24
$254.1M
$41.3M
Total Assets
NEWT
NEWT
TOI
TOI
Q4 25
$2.7B
$164.7M
Q3 25
$2.4B
$163.6M
Q2 25
$2.1B
$159.8M
Q1 25
$2.1B
$164.0M
Q4 24
$2.1B
$172.7M
Q3 24
$1.7B
$179.2M
Q2 24
$1.6B
$179.6M
Q1 24
$1.5B
$204.5M
Debt / Equity
NEWT
NEWT
TOI
TOI
Q4 25
2.06×
Q3 25
1.94×
Q2 25
2.11×
Q1 25
2.56×
Q4 24
2.39×
Q3 24
2.33×
Q2 24
2.38×
Q1 24
2.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEWT
NEWT
TOI
TOI
Operating Cash FlowLast quarter
$-579.2M
$3.2M
Free Cash FlowOCF − Capex
$-579.3M
$2.2M
FCF MarginFCF / Revenue
-790.0%
1.5%
Capex IntensityCapex / Revenue
0.1%
0.7%
Cash ConversionOCF / Net Profit
-29.64×
TTM Free Cash FlowTrailing 4 quarters
$-1.0B
$-27.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEWT
NEWT
TOI
TOI
Q4 25
$-579.2M
$3.2M
Q3 25
$-167.3M
$-12.6M
Q2 25
$-199.8M
$-10.2M
Q1 25
$-60.7M
$-5.0M
Q4 24
$-153.0M
$4.2M
Q3 24
$-25.7M
$819.0K
Q2 24
$2.9M
$-15.7M
Q1 24
$-38.7M
$-15.9M
Free Cash Flow
NEWT
NEWT
TOI
TOI
Q4 25
$-579.3M
$2.2M
Q3 25
$-167.3M
$-13.2M
Q2 25
$-199.9M
$-11.4M
Q1 25
$-60.7M
$-5.3M
Q4 24
$-153.5M
$2.4M
Q3 24
$-25.9M
$417.0K
Q2 24
$2.9M
$-17.5M
Q1 24
$-38.7M
$-16.5M
FCF Margin
NEWT
NEWT
TOI
TOI
Q4 25
-790.0%
1.5%
Q3 25
-223.3%
-9.7%
Q2 25
-284.7%
-9.5%
Q1 25
-91.6%
-5.1%
Q4 24
-203.6%
2.4%
Q3 24
-41.2%
0.4%
Q2 24
4.7%
-17.7%
Q1 24
-66.5%
-17.4%
Capex Intensity
NEWT
NEWT
TOI
TOI
Q4 25
0.1%
0.7%
Q3 25
0.0%
0.4%
Q2 25
0.1%
1.0%
Q1 25
0.1%
0.3%
Q4 24
0.6%
1.8%
Q3 24
0.4%
0.4%
Q2 24
0.1%
1.9%
Q1 24
0.1%
0.6%
Cash Conversion
NEWT
NEWT
TOI
TOI
Q4 25
-29.64×
Q3 25
-9.35×
Q2 25
-14.58×
Q1 25
-6.48×
Q4 24
-8.35×
Q3 24
-2.15×
Q2 24
0.27×
Q1 24
-4.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NEWT
NEWT

Segment breakdown not available.

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

Related Comparisons